Index of reports
> Disability (1)
Below is the selection of side effect reports (a.k.a. adverse event reports) related to Nipent (Pentostatin) disability. The selected reports were submitted to the FDA during the sample period of about a year.
Possible Nipent side effects in male
Reported by a health professional (non-physician/pharmacist) from United States on 2011-12-01
Patient: male, weighing 127.4 kg (280.3 pounds)
Reactions: Dysphagia, Blood Lactate Dehydrogenase Increased, Alanine Aminotransferase Increased, Muscular Weakness, Polymyositis, Connective Tissue Disorder, Musculoskeletal Disorder, Aspartate Aminotransferase Increased, Blood Uric Acid Increased, Mastication Disorder
Adverse event resulted in: disablity
Drug(s) suspected as cause:
Nipent
Dosage: 10 mg, not reported
Indication: Chronic Lymphocytic Leukaemia
Start date: 2011-09-01
End date: 2011-09-01
(Rituximab)
Dosage: 945 mg, not reported
Indication: Chronic Lymphocytic Leukaemia
Start date: 2011-09-01
End date: 2011-09-01
Cyclophosphamide
Dosage: 1512 mg, not reported
Indication: Chronic Lymphocytic Leukaemia
Start date: 2011-09-01
End date: 2011-09-01
|